Osteoporosis, Bisphosphonates, and Dental Implants: What Patients Need to Know

Osteoporosis and Bone Health: The Dental Dimension

Osteoporosis — reduced bone mineral density and microarchitectural deterioration of bone tissue — affects approximately 1 million Australians, predominantly women over 50. The condition increases fracture risk across the skeleton, including the jaw bones that support teeth and dental implants.

For Townsville patients with osteoporosis, several dental considerations are important: the effect of the disease itself on jaw bone and tooth support, the impact of the medications used to treat osteoporosis on healing after dental procedures, and the planning requirements for dental implants in this population.

How Osteoporosis Affects the Mouth and Jaw

Osteoporosis reduces bone density throughout the skeleton, including the alveolar bone (the ridge of bone that holds teeth in their sockets) and the basal bone of the mandible and maxilla. Several oral manifestations have been associated with low bone mineral density:

Tooth loss: Studies including the Osteoporosis and Periodontal Disease Study (OPPD) have found that women with osteoporosis are three times more likely to experience tooth loss than those with normal bone density, likely due to reduced alveolar bone support in the presence of gum disease.

Periodontal disease: Low bone mineral density appears to amplify bone loss around teeth in patients with periodontitis. The combination of systemic bone loss and local bacterial destruction of alveolar bone accelerates attachment loss.

Reduced implant bone volume: Patients with osteoporosis who have lost teeth often have reduced residual bone height and width, making implant placement more challenging and potentially requiring bone grafting.

Jaw fracture risk: Severe osteoporosis can increase the risk of mandibular fracture after tooth extraction, particularly in older patients with extensive disease.

The Bisphosphonate Problem

What bisphosphonates do

Bisphosphonates are the most commonly prescribed class of medication for osteoporosis. Common oral bisphosphonates include:

• Alendronate (Fosamax) — weekly tablet
• Risedronate (Actonel) — weekly or monthly tablet
• Ibandronate (Boniva) — monthly tablet or quarterly infusion

Intravenous bisphosphonates include:

• Zoledronate (Zometa, Aclasta) — annual infusion for osteoporosis; more frequent infusion at higher doses for bone metastases in cancer

Bisphosphonates work by inhibiting osteoclasts — the bone-resorbing cells responsible for normal bone turnover. By slowing bone breakdown, they increase bone mineral density and reduce fracture risk. However, bone turnover is also essential for healing after injury. Bisphosphonates accumulate in bone and remain active for years or even decades after the drug is stopped.

What is MRONJ?

Medication-related osteonecrosis of the jaw (MRONJ) is a condition in which exposed jaw bone fails to heal, typically following an oral surgical procedure (extraction, implant surgery, periodontal surgery) in a patient taking antiresorptive or antiangiogenic medications.

MRONJ presents as:

• Exposed, non-healing bone in the mouth
• Pain, swelling, or infection around the exposed area
• Sometimes initial detection as a non-healing extraction socket weeks or months after tooth removal

The condition can be chronic, difficult to treat, and in severe cases may require surgical debridement or resection of affected bone.

Risk stratification: oral vs intravenous bisphosphonates

The risk of MRONJ varies significantly by medication type, dose, and duration:

The key practical point: most Townsville patients taking oral Fosamax for osteoporosis are in the low-risk category. However, the risk is not zero, and it increases with duration of treatment beyond 4 years and in the presence of additional risk factors.

Additional risk factors for MRONJ:

• Corticosteroid therapy (long-term prednisone)
• Smoking
• Diabetes
• Immunosuppression
• Poor oral hygiene and untreated periodontal disease
• Previous chemotherapy or radiotherapy to the head and neck
• Anatomical factors (denture-related trauma in edentulous patients)

Dental Implants and Osteoporosis: Evidence and Practice

Can patients on bisphosphonates receive dental implants?

The evidence on this question is mixed and evolving. Several systematic reviews have examined implant outcomes in patients taking bisphosphonates:

• A 2018 meta-analysis by Ata-Ali et al. found a statistically significant but clinically modest reduction in implant survival rates in bisphosphonate-treated patients compared to controls (95.5% vs 97.1% survival at 5 years)
• A 2020 systematic review by Sievert et al. found no significant difference in early implant failure rates between oral bisphosphonate users and non-users
• MRONJ associated specifically with implant placement (rather than extraction) is documented but rare

The current consensus among implant specialists is that dental implants are not absolutely contraindicated in patients taking oral bisphosphonates for osteoporosis, but:

• Duration of use and risk factor profile must be assessed
• Patients should be comprehensively informed of the increased risk
• Cases are best managed by an implant specialist (oral and maxillofacial surgeon or prosthodontist) rather than a general dentist
• Meticulous surgical technique and minimising trauma are essential

The drug holiday controversy

“Drug holiday” refers to temporary cessation of bisphosphonate therapy before and after dental implant surgery to improve healing conditions. This is controversial because:

1. Bisphosphonates have a half-life in bone of 10 years or more — stopping the drug for several weeks to months does not meaningfully reduce its presence in jaw bone
2. Stopping bisphosphonates increases fracture risk in osteoporotic patients
3. There is no strong clinical evidence that drug holidays reduce MRONJ risk

Current consensus guidelines from the American Association of Oral and Maxillofacial Surgeons (2022) do not routinely recommend drug holidays for patients on oral bisphosphonates for osteoporosis. The decision should involve the patient’s prescribing doctor (endocrinologist or GP) and the treating oral surgeon, weighing the fracture risk of cessation against any potential benefit for healing.

Pre-implant assessment for osteoporosis patients

Before placing implants in a patient with osteoporosis or bisphosphonate history:

• Full medical history including duration and dose of all bisphosphonate or denosumab use
• Risk factor assessment (diabetes, smoking, corticosteroids, immune status)
• CBCT imaging to assess jaw bone density and volume at the implant site
• Discussion of alternatives (implant-retained dentures using fewer implants, conventional dentures, bridges)
• Patient consent documenting the specific risks and the decision-making process

Denosumab (Prolia): A Different Mechanism, Similar Concerns

Denosumab (Prolia), given as a subcutaneous injection every 6 months, is increasingly used for osteoporosis. It works differently from bisphosphonates — it inhibits RANKL, a signalling molecule required for osteoclast development. Unlike bisphosphonates, it does not accumulate in bone and its effects reverse more quickly after cessation.

However, denosumab carries a similar MRONJ risk to intravenous zoledronate for the osteoporosis indication. Additionally, denosumab cessation requires particular care — rapid rebound bone resorption can occur after stopping denosumab, dramatically increasing fracture risk. This means the drug holiday strategy is even less viable for denosumab patients than for bisphosphonate patients.

Dental treatment should ideally be completed during the second half of the 6-month denosumab cycle (3–6 months after the last injection) when the drug’s effect on osteoclasts is at its nadir.

Practical Guidance for Townsville Patients

Tell your dentist at every visit if you take bisphosphonates or denosumab. List the specific medication, dose, and how long you have been taking it. This information changes how the dentist plans treatment.

Maintain excellent oral hygiene. The best way to reduce MRONJ risk is to avoid the need for tooth extractions and oral surgery. Regular preventive visits, prompt treatment of dental decay, and management of gum disease all reduce the likelihood of needing invasive procedures.

Do not delay treatment. Patients sometimes defer dental treatment out of fear of complications. Untreated infection or progressive decay will eventually require more invasive treatment than early intervention. It is safer to manage dental problems while they are small.

Ask your dentist for a dental review before starting bisphosphonate therapy. If you are about to commence bisphosphonate treatment for osteoporosis, a full dental examination to identify and treat any existing dental disease before starting the medication is strongly recommended. This is the standard of care.

Consider specialist referral for implants. If you are on long-term bisphosphonates and considering dental implants, an opinion from an oral and maxillofacial surgeon or experienced prosthodontist is recommended before committing to treatment. Townsville has oral and maxillofacial surgical services at the hospital; private specialist implant dentists are also available.

For more information on dental implant eligibility generally, see the dental implant candidates guide and the dental implants with bone loss guide.